On May 20, 2019, the United States, acting on behalf of the Food and Drug Administration (FDA), filed a civil complaint against PharMEDium Services, LLC in the U.S. District Court for the Northern District of Illinois, and the parties simultaneously filed an agreed consent decree of permanent injunction, entered the same day by U.S. District Judge Virginia M. Kendall. This article revisits that case seven years later — not as breaking news, but as a teaching case, because no new pharmaceutical consent decree was identified in FDA’s public enforcement record during this reporting window, and PharMEDium remains the clearest available precedent for how a 503B outsourcing facility’s aseptic processing failures can escalate to the most severe civil enforcement tool short of seizure or criminal prosecution. PharMEDium was, at the time, the largest 503B outsourcing facility operator in the United States, compounding and distributing sterile injectable preparations — including oxytocin and morphine sulfate — to hospitals nationwide, and had been acquired by AmerisourceBergen Corporation in 2015 for approximately $2.6 billion.
The 2019 decree did not arrive without warning. It followed a multi-year FDA inspection history at PharMEDium’s sites beginning around 2016–2017, during which the company received a series of FDA Form 483 inspectional observations — findings that are, by definition, individual investigator observations rather than a final agency determination, but which in PharMEDium’s case triggered voluntary product recalls and a substantial, self-imposed reduction in production capacity well before the decree was entered. AmerisourceBergen’s own U.S. Securities and Exchange Commission (SEC) 8-K and 10-Q disclosures from 2018–2019 described this curtailment as a material drag on segment revenue, meaning the decree formalized restrictions the company had already largely accepted rather than imposing them from a standing start. This is the “483 → recall → voluntary shutdown → consent decree” arc that recurs across sterile-manufacturing enforcement, and it is the arc every quality organization should be tracking in its own inspection history, because by the time a company reaches this stage, the CGMP conversation has moved from remediation to litigation.
The complaint alleged that PharMEDium and two named individuals — company president Scott Aladeen and Vice President for Quality and Research & Development Warren Horton — manufactured and distributed drugs that were adulterated (prepared, packed, or held under insanitary conditions such that they may have been contaminated with filth or rendered injurious to health, and manufactured without adherence to current Good Manufacturing Practice), misbranded, and in some instances unapproved new drugs. Mapped to XGene’s Warning Letter deficiency framework, the underlying FDA findings across PharMEDium’s Memphis, Sugar Land, Dayton, and Lake Forest sites cluster into three categories: facility and environmental control deficiencies consistent with insanitary conditions; aseptic processing and sterility assurance failures, which formed the core allegation; and quality unit and investigation deficiencies reflecting inadequate CAPA (Corrective and Preventive Action) effectiveness following sterility-related findings. It is worth being precise about what “aseptic processing failure” means operationally — FDA’s sterile-manufacturing enforcement record does not treat any single control (environmental monitoring, personnel gowning, or terminal testing alone) as sufficient; contamination control is a function of facility design, personnel qualification, process design, sterilization assurance, environmental monitoring, and media fill performance acting together, and a decree of this severity typically reflects failure across more than one of those elements simultaneously.
Operationally, the decree’s terms are instructive for any quality or legal team modeling what a consent decree actually requires day to day. The Dayton, New Jersey and Sugar Land, Texas facilities were permitted to continue commercial operations, and the Lake Forest, Illinois headquarters to continue administrative operations, conditioned on compliance with the decree. Within 60 days of entry, PharMEDium was required to commence an audit inspection of the Dayton and Sugar Land facilities by an independent CGMP expert to certify conformity. The Memphis facility — evidently the site of the most serious findings — could not resume commercial operations until PharMEDium submitted a work plan approved by FDA, followed by an audit inspection and certification by an independent expert confirming that facilities, methods, and controls at Memphis, and quality oversight from Lake Forest, complied with the decree. Ongoing FDA inspection access and reporting obligations continued for the life of the decree. Perhaps most notable for boards and general counsels: the decree bound Aladeen and Horton personally as individuals responsible for establishing and maintaining compliance — a recurring feature of FDA sterile-manufacturing decrees that extends liability beyond the corporate entity to named executives, and a fact pattern every Chief Manufacturing Officer and VP of Quality should register before assuming a decree is a company-only exposure.
The commercial impact was immediate and, unusually for an enforcement action, directly felt by patients rather than only by shareholders. PharMEDium was the dominant national supplier of outsourced sterile compounded preparations to U.S. hospitals, and contemporaneous trade press described resulting shortages of ready-to-use injectable products, including oxytocin and opioid preparations, as hospitals scrambled for alternative 503B suppliers. Exact lost-revenue figures were not consistently broken out in AmerisourceBergen’s public disclosures, but the $2.6 billion acquisition price provides a scale reference for the asset that the enforcement action impaired for years.
Historical precedent helps calibrate what comes next for a company in PharMEDium’s position. The Ranbaxy Laboratories decree, entered January 25, 2012 in the District of Maryland after systemic data integrity failures, disrupted the company’s U.S. operations for more than three years and was followed by a separate $500 million criminal and False Claims Act settlement in 2013 — a reminder that a consent decree and a criminal resolution can run on parallel, not sequential, tracks. The Hi-Tech Pharmacal decree, entered in 2006 for sterile manufacturing failures at its Amityville, New York facility, required a court-appointed independent expert to review batch records before release and audit the facility semi-annually; that expert reviewed more than 200 batch records over four years before FDA agreed to a modified order — an operational model for independent-expert oversight that has since become standard for sterile-product decrees generally. Able Laboratories, by contrast, is the cautionary extreme: its 2005 consent decree, following systematic deletion of dissolution test failures at its Toms River, New Jersey oral solid dosage facility, ultimately ended in the company’s closure, because the commercial burden of compliance exceeded its ability to continue operating. PharMEDium’s five-year “earn your way out” relief provision — under which the government agreed not to oppose a petition for relief if the company maintained continuous compliance for at least five years after satisfying facility-specific obligations — sits closer to the Hi-Tech model than the Able Laboratories outcome, and is a standard clause worth understanding before any company assumes a decree is permanent or, conversely, that it will simply expire.
For compounding pharmacies, 503B outsourcing facilities, and sterile-injectable manufacturers reading this in 2026, the lesson is not that FDA moved harshly in 2019 — it is where the threshold sits. FDA does not typically escalate to a consent decree from a single inspection; it escalates when a company’s CAPA response to repeated 483 observations and, generally, a prior Warning Letter fails to demonstrate that the underlying system, not just the cited observation, has been corrected. The pattern visible in this month’s sterile-products Warning Letter activity — including recent aseptic processing and data integrity findings at other compounding and sterile-injectable manufacturers — is the early stage of the same arc PharMEDium illustrates at its most severe endpoint. Quality organizations that treat a 483 response as a documentation exercise rather than an evidentiary one are, in FDA’s own enforcement history, the companies most likely to be reading their own consent decree within a few years.
XGene Consulting supports quality and executive teams at each stage of this arc — Warning Letter and 483 remediation with root-cause assessment and CAPA design built to withstand FDA reinspection scrutiny, not just close the observation on paper; consent decree readiness assessment and quality system gap analysis for companies approaching negotiation with the Department of Justice (DOJ) and FDA; and third-party Expert support, including preparation of the technical documentation an independent CGMP expert will need to certify conformity under decree terms. If your organization is managing sterile manufacturing risk anywhere along this continuum, the PharMEDium case is worth studying in detail before it becomes your own.